This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Happy Day for Arena Bulls, Bears as Belviq Launch Finally Arrives

SAN DIEGO ( TheStreet) -- Areniacs rejoice! The DEA has finally published the rule establishing Arena Pharmaceuticals' (ARNA - Get Report) weight-loss pill Belviq as a Schedule IV drug and allowing the commercial launch to begin in 30 days.

Arena shorts rejoice! You've been waiting more than 10 months for Arena and partner Eisai to finally start posting disappointing sales of Belviq.

Today is a happy day for everyone.

Well, not everyone. Some of the Areniacs are pissed off at DEA for taking so long to decide on Belviq's abuse potential.

Too funny.

Back to serious matters, while Arena hasn't yet commented publicly on the final DEA schedulings, the company has said previously that Belviq is ready to launch. DEA did not grant Arena's request to waive the mandatory 30-day waiting period, so assume Belviq marketing will begin in early June. Once launched, Belviq will compete against Vivus' (VVUS - Get Report) weight-loss pill Qsymia, which has posted weak sales to date.

DEA's decision to place Belviq in the Schedule IV, or "low potential for abuse" category was expected.

Arena shares were up 44 cents, or 6%, to $7.96 in early Tuesday trading.
Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ARNA $1.71 -0.58%
VVUS $1.58 -4.24%
AAPL $93.64 -0.11%
FB $118.57 0.84%
GOOG $698.21 0.75%


Chart of I:DJI
DOW 17,891.16 +117.52 0.66%
S&P 500 2,081.43 +16.13 0.78%
NASDAQ 4,817.5940 +42.2360 0.88%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs